We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00911495
First Posted: June 2, 2009
Last Update Posted: September 23, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pfizer
  Purpose
This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor, in adults with stable sickle cell disease. The study will assess safety, pharmacokinetics, and microvascular effects of intravenous GMI-1070 in the outpatient setting.

Condition Intervention Phase
Sickle Cell Disease Drug: GMI-1070 Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/Phase 2 Study of the Safety, Pharmacokinetics, and Microvascular Effect of Titrating Doses of Intravenous GMI-1070, a Pan-Selectin Inhibitor, in Adults With Sickle Cell Disease

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Safety as Measured by the Number of Participants With Adverse Events [ Time Frame: 28 days ]

Secondary Outcome Measures:
  • Total Plasma Clearance [ Time Frame: 48 hours ]
  • Volume of the Central Compartment [ Time Frame: 48 hours ]
  • Intercompartmental Clearance [ Time Frame: 48 hours ]
  • Volume of the Peripheral Compartment [ Time Frame: 48 hours ]

Other Outcome Measures:
  • Blood Flow and Biomarkers of Adhesion [ Time Frame: 48 hours ]
    As an exploratory outcome mean change in microvascular blood flow from baseline to each time point was measured. Microvascular blood flow was also measured as microFI, perfused vessel density, and RBC velocity.


Enrollment: 15
Study Start Date: May 2009
Study Completion Date: September 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GMI-1070 Drug: GMI-1070
Intravenous GMI-1070 given as two doses over the course of one day

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 to 45 years
  • Established diagnosis of SCD-SS or SCD-SB0-thal
  • At medical baseline, with no evidence of worsening of disease over the last 3 months
  • Available and agree to return for follow-up visits for the full duration of the study
  • Able to cooperate with study procedures
  • Documented and observed written informed consent

Exclusion Criteria:

  • Vaso-occlusive crisis
  • Recent major surgery, hospitalization, infection, significant bleeding, cerebrovascular accident or seizure, or transfusion
  • Currently receiving, or has received within the previous 4 weeks, any other investigational agent
  • Pregnant or lactating female; or female of childbearing age unable or unwilling to comply with birth control or abstinence during the course of the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00911495


Locations
United States, California
Children's Hospital & Research Center Oakland
Oakland, California, United States, 94609
University of California at Davis, CCRC
Sacramento, California, United States, 95817
United States, North Carolina
Duke Comprehensive Sickle Cell Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Helen Thackray, MD GlycoMimetics Incorporated
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00911495     History of Changes
Other Study ID Numbers: GMI-1070-103
First Submitted: May 27, 2009
First Posted: June 2, 2009
Results First Submitted: September 11, 2012
Results First Posted: May 3, 2013
Last Update Posted: September 23, 2016
Last Verified: May 2013

Keywords provided by Pfizer:
Sickle Cell Disease

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn